Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Acute Lymphocytic Leukemia Clinical Trial

Official title:

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02374333
• Other study ID #: 13BT022, 819851
• Status: Completed
• Phase: Phase 1
• Start date: March 25, 2014
• Est. completion date: September 2, 2021

Study information

• Verified date: September 2021
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in patients with relapsed or refractory CD19+ leukemia and lymphoma that was previously treated with cell therapy. This study is targeting pediatric patients aged 1-24 years with CD19+ B cell malignancies with no available curative treatment options (such as autologous or allogeneic stem cell transplantation) who have a limited prognosis with currently available therapies and were previously treated with a B cell directed engineered cell therapy product.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: September 2, 2021
• Est. primary completion date: September 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 24 Years

Eligibility

Inclusion Criteria:

Male and female subjects with documented CD19+ B cell malignancies and no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to <2 year survival) with currently available therapies will be enrolled:

1. Eligible diseases: CD19+ leukemia or lymphoma. In general, these will be patients with:

1. ALL without curative options for therapy, including those not eligible for allogeneic SCT. Patient may be in any complete response, or patient may have active disease but responding or stable after most recent therapy.The intent is not to enroll patients with no degree of disease control or rapidly increasing disease burden between enrollment and cell infusion.

2. Diffuse large cell lymphoma or other high-grade NHL, previously identified as CD19+ including residual disease after primary therapy and not eligible for autologous SCT; relapsed after prior autologous SCT; beyond 1st CR with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT.

2. Patients previously treated with B cell directed engineered cell therapy are eligible if they meet one of the following criteria:

1. partial response or no response to prior cell therapy

2. relapsed after prior cell therapy

3. demonstrated B cell recovery suggesting loss of engineered cells.

3. Documented CD19 expression (after previous B cell directed cell therapy, if applicable)

4. Age 1 to 24 years

5. Expected survival > 12 weeks

6. Creatinine < 2.5 mg/dl and less than 2.5x normal for age

7. Bilirubin <2.0 mg/dl

8. Adequate pulmonary function defined as < Grade 3 hypoxia

9. Adequate cardiac function defined as LVSF = 28% confirmed by ECHO

10. Adequate performance status (Lansky or Karnofsky score =50)

11. Patients with relapsed disease after prior allogeneic SCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and

1. Have no active GVHD and require no immunosuppression

2. Are more than 4 months from transplant (6 months at infusion)

12. Patients with CNS3 disease will be eligible if CNS disease is responsive to therapy

13. For those patients who require leukapheresis for T cell collection (i.e. no previously collected product exists), adequate venous access for apheresis or eligible for appropriate catheter placement, and no other contraindications for leukapheresis.

14. Voluntary informed consent is given.

Exclusion Criteria:

1. Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion.

2. Uncontrolled active infection.

3. Active hepatitis B or hepatitis C infection.

4. Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.

5. Presence of grade 2-4 acute or extensive chronic GVHD.

6. Under treatment for GVHD.

7. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity

8. Any uncontrolled active medical disorder that would preclude participation as outlined.

9. HIV infection

Related Conditions & MeSH terms

• Acute Lymphocytic Leukemia
• Diffuse Large Cell Lymphoma
• Leukemia
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Biological:
• huCART19

Locations

Country	Name	City	State
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of study related adverse events defined as NCI CTCAE 4.0 > grade 3 possibly, probably, or definitely related to study treatment.		Study treatment until Week 24